Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCU500
- Development stage
- Unknown
- Lead developer
- Ocugen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Mucosal
01
Overview
OCU500 is a mucosal vaccine candidate developed by Vaccigen for the prevention of COVID-19. Unlike traditional injectable vaccines, OCU500 is designed for mucosal administration to induce a localized immune response directly in the respiratory tract, which is the primary entry point for the SARS-CoV-2 virus. By stimulating the production of secretory IgA antibodies and activating local T-cells in the mucosal lining, the vaccine aims to provide a robust first line of defense that could potentially reduce both infection rates and viral transmission. OCU500 is currently in Phase 1/2 clinical development.
- Other names
- OCU500 mucosal vaccineOCU-500 mucosal vaccineOCU 500 mucosal vaccine
Beyond the preview
Go deeper on OCU500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCU500.